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A B S T R A C T 16 
 17 
Sleeping sickness is an infectious disease that is caused by the protozoan parasite 18 
Trypanosoma brucei. The second stage of the disease is characterised by the parasites 19 
entering the brain. It is therefore important that sleeping sickness therapies are able to cross 20 
the blood-brain barrier. At present, only three medications for chemotherapy of the second 21 
stage of the disease are available. As these trypanocides have serious side effects and are 22 
difficult to administer, new and safe anti-trypanosomal brain-penetrating drugs are needed. 23 
For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity 24 
against bloodstream forms of T. brucei. The concentration of the drug required to reduce the 25 
growth rate of the parasites by 50% was 29.1 μM and to kill all trypanosomes was 125 μM. 26 
Importantly, temozolomide did not affect the growth of human HL-60 cells up to a 27 
concentration of 300 μM. Cell cycle analysis revealed that temozolomide induced DNA 28 
damage and subsequent cell cycle arrest in trypanosomes exposed to the compound. As drug 29 
combination regimes often achieve greater therapeutic efficacy than monotherapies, the 30 
interactions of temozolomide with the trypanocides eflornithine and melarsoprol, 31 
respectively, was determined. Both combinations were found to produce an additive effect. In 32 
conclusion, these results together with well-established pharmacokinetic data provide the 33 
basis for in vivo studies and potentially for clinical trials of temozolomide in the treatment of 34 
T. brucei infections and a rationale for its use in combination therapy, particularly with 35 
eflornithine or melarsoprol. 36 
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1. Introduction 44 
 45 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a tropical 46 
neglected disease occurring in rural areas of sub-Saharan Africa (Steverding, 2008). The 47 
disease is caused by the protozoan parasite Trypanosoma brucei and transmitted to humans 48 
by the bite of infected tsetse flies (Glossina spp.). At first, the trypanosomes live and multiply 49 
extracellularly in the blood and the lymphatic fluids of their human host (WHO, 2016). Then, 50 
after months or years, the parasites invade the central nervous system. At this stage, the 51 
typical symptoms are sleeping disorders and apathy, the characteristic signs that gave the 52 
disease its name (WHO, 2017). Without chemotherapy, sleeping sickness is eventually fatal. 53 
Unfortunately, only two drugs (melarsoprol and eflornithine) and one drug combination 54 
(nifurtimox/eflornithine) are available for treatment of the neurological or second (late) stage 55 
of the disease (Croft, 1997; Fairlamb, 2003; Steverding, 2010). All these treatments have 56 
serious side effects and drawbacks. For example, melarsoprol can cause reactive 57 
encephalopathy which is fatal in 3-10% of cases (WHO, 2017) while the treatment regime of 58 
eflornithine is complex (iv infusion of 400 mg/kg/day 6 hourly) and requires hospital 59 
admission (Kuzoe, 1993). Although two new drug candidates, fexinidazole and SCYX-7158, 60 
are currently undergoing clinical trials (phase II/III and phase I, respectively; DNDi, 2017), 61 
their licensing for treatment of sleeping sickness may still take years. 62 
Another strategy to discover new therapies for tropical parasitic diseases is the testing of 63 
existing, already approved drugs (Caffrey and Steverding, 2008). As the toxicological and 64 
pharmacological properties of licensed drugs are established, a more rapid application of 65 
existing drugs for treatment of a neglected tropical disease with limited clinical trials may be 66 
possible. This has been shown in the case of the nifurtimox/eflornithine combination therapy 67 
which development took only 8 years from two initial clinical trials in Uganda in 2001 and 68 
2004 followed by a demonstration trial and a whole multicentric study in the Democratic 69 
Republic of Congo until the drug combination was added to the WHO Essential Medicine 70 
List for treatment of second stage T. gambiense sleeping sickness in April 2009 (Yun et al., 71 
2010). 72 
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An interesting class of drugs with anti-trypanosomal activity are anti-cancer agents as 73 
has been shown for clinical approved topoisomerase and proteasome inhibitors (Deterding et 74 
al., 2005; Steverding and Wang, 2009). However, in the case of sleeping sickness, drugs are 75 
needed that are able to cross the blood-brain barrier in order to treat the neurological stage of 76 
the disease. Here we pre-clinically evaluate the toxic effect of a glioblastoma 77 
chemotherapeutic agent on trypanosomes. The compound temozolomide (Fig. 1) was 78 
investigated for its trypanocidal activity alone and in combination with the anti-HAT drugs 79 
eflornithine or melarsoprol against bloodstream forms of T. brucei. 80 
 81 
2. Materials and Methods 82 
 83 
2.1. Drugs 84 
 85 
Temozolomide and eflornithine (DL-α-difluoromethylornithine) were purchased from 86 
Sigma-Aldrich (Gillingham, UK) and Enzo Life Sciences Ltd. (Exeter, UK), respectively. 87 
Melarsoprol was a gift from Sanofi-Aventis Deutschland GmbH (Frankfurt, Germany). 88 
 89 
2.2. Cell Culture 90 
 91 
Bloodstream forms of the T. brucei clone 427-221a (Hirumi et al., 1980) were grown in 92 
Baltz medium (Baltz et al., 1985) while human myeloid leukaemia HL-60 cells (Collins et al., 93 
1977) were cultured in RPMI medium (Moore et al., 1967). Both media were supplemented 94 
with 16.7% heat-inactivated foetal bovine serum. Trypanosomes and human cells were 95 
maintained at 37 °C in a humidified atmosphere containing 5% carbon dioxide. 96 
 97 
2.3. Toxicity assay 98 
 99 
Toxicity assays were performed according to the method described by Merschjohann et 100 
al. (2001) with some modifications. In brief, cells were seeded in 96-well plates in a final 101 
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volume of 200 μl of appropriate medium containing various concentration of temozolomide 102 
(twofold dilutions from 300 μM to 2.34375 μM) and 1 % DMSO. The initial cell densities 103 
were 1  104/ml for bloodstream-form trypanosomes and 1  105/ml for human myeloid HL-104 
60 cells. After 24 h incubation, 20 μl of 0.5 mM resazurin in PBL (sterile filtered) was added 105 
and the cells were incubated for a further 48 h. The concentration of the resazurin stock 106 
solution and the amount of the dye added were the same as those for the commercial Alamar 107 
Blue assay (O’Brien et al., 2000). It should be also noted that the addition of resazurin does 108 
not have any negative effect on the determination of MIC and GI50 values. This was 109 
previously shown when the resazurin assay was compared with direct cell counting 110 
(Merschjohann et al., 2001). Subsequently, the absorbance was read on a microplate reader 111 
using a test wavelength of 570 nm and a reference wavelength of 630 nm. The 50 % growth 112 
inhibition (GI50) value, i.e., the concentration of the drug necessary to reduce the growth rate 113 
of cells by 50 % compared to the control, was determined by linear interpolation according to 114 
the method described by Huber and Koella (1993). The minimum inhibitory concentration 115 
(MIC) value, i.e., the concentration of the drug at which all cells were killed, was determined 116 
microscopically. 117 
 118 
2.4. Cell cycle analysis 119 
 120 
Bloodstream forms of T. brucei (5  105/ml) were incubated with 100 μM temozolomide 121 
or 0.5% DMSO for 21 h. After harvesting by centrifugation at 850  g and washing once with 122 
PBS/1% glucose (PBSG), cells were re-suspended in 300 μl PBSG and fixed with 700 μl ice-123 
cold ethanol for 30 min. After diluting with 500 μl PBSG, cells were centrifuged, washed 124 
once with PBSG and re-suspended in the same buffer. The cells were stained with propidium 125 
iodide staining solution (5 μl/100 μl cell suspension) and incubated with 200 μg/ml RNase A. 126 
After 1 h incubation at room temperature, cells were analysed on a CyFlow® Cube 6 flow 127 
cytometer. Debris and cell fragments were excluded from analysis through gating on forward 128 
and site scatter properties, and 50,000 cells were analysed. 129 
 130 
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2.5. Determination of drug interactions and isobologram construction 131 
 132 
The interactions between temozolomide and anti-HAT drugs were determined by a 133 
modified isobolographic method (Fivelman et al., 2004). Based on GI50 values, the maximum 134 
concentration of individual drugs was set at 5  GI50 ensuring that the GI50 was at the 135 
midpoint of the serial dilution. The highest concentrations of solutions were prepared in 136 
proportions of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 of temozolomide and anti-HAT drugs 137 
(eflornithine and melarsoprol, respectively), which were then twofold serially diluted (6 138 
dilution steps). The assay was set up in 96-well plates and wells without drugs served as 139 
controls. All wells contained 1 % DMSO. The initial cell density was 1  104 140 
trypanosomes/ml. The assay was evaluated and GI50 values calculated as described above. 141 
The fractional inhibitory concentration (FIC) at the GI50 value was calculated as FIC = 142 
GI50(combination)/GI50(alone). The sum of FICs (FIC) was computed as FIC = FIC(drug A) + 143 
FIC(drug B). The mean sum of FICs (xFIC) was averaged over the FICs. Isobolograms were 144 
built by plotting the FIC of each drug ratio. The xFICs were used to classify the interactions 145 
according to Odds (2003). An xFIC of ≤ 0.5, between 0.5 and 4, and of ≥4 indicates 146 
synergy, indifference and antagonism, respectively. 147 
 148 
3. Results and discussion 149 
 150 
The trypanocidal and cytotoxic activity of the anti-glioblastoma drug temozolomide was 151 
evaluated with bloodstream forms of T. brucei and human myeloid leukaemia HL-60 cells. 152 
Temozolomide showed a concentration-dependent inhibitory effect on the growth of T. 153 
brucei bloodstream forms with an MIC value of 125 μM and a GI50 value of 29.1 μM (Fig. 154 
2). The trypanocidal activity of temozolomide was within the range of previously reported 155 
cytotoxic activity of the drug against various glioblastoma cell lines, with published GI50 156 
values ranging between 10 μM to 250 μM (Gaspar et al., 2010; Perazzoli et al., 2015; Lee et 157 
al., 2016). In addition, the GI50 value of temozolomide was similar to that of eflornithine 158 
(23.9 μM determined under the same experimental conditions), one of the drugs used to treat 159 
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the second stage of sleeping sickness. Crucially important, temozolomide did not show any 160 
cytotoxic effect against human HL-60 cells up to a concentration of 300 μM (Fig. 2). HL-60 161 
cells are usually used as reference as their sensitivity for approved trypanocides is well 162 
established (Merschjohann et al., 2001; Steverding and Wang, 2009). 163 
To investigate the anti-trypanosomal mechanism of action of temozolomide, the DNA 164 
content of bloodstream form trypanosomes exposed to the drug was analysed by flow 165 
cytometry. After 21 h exposure to 100 μM temozolomide, a 2.8-fold decrease, and a 6.4-fold 166 
and a 1.7-fold increase in the proportion of cells with normal (2C), lower (<2C) and double 167 
(4C) DNA content were observed, respectively (Fig. 3). This finding indicates that 168 
trypanosomes exposed to the drug are unable to finish cell division after completing DNA 169 
synthesis (cell arrest at the G2-M boundary) followed by fragmentation of DNA with 170 
subsequent cell death. The trypanocidal mode of action of temozolomide resembles the 171 
cytotoxic mechanism of the drug reported previously for human glioblastoma cells (Hirose et 172 
al., 2001). The cytotoxic activity of temozolomide is based on its alkylating activity of 173 
guanine and adenine (Denny et al., 1994). Although accounting for only 5% of the total 174 
adducts formed, O6-methylguanine plays the critical role in the antitumor activity of drug. 175 
Even though the methyl group in O6-methylguanine can be removed by O6-methylguanine-176 
DNA methyl transferase (MGMT), cells with low levels of this DNA repair enzyme are 177 
sensitive to the cytotoxic action of temozolomide (Dolan et al., 1991). In the case of T. 178 
brucei, it seems that this protozoan does not have this enzyme as no MGMT gene was found 179 
when searching the TriTrypDB database. Non-removal of the methyl group at position O6 of 180 
guanine will lead to mispairing of the base with thymine during the next DNA replication. 181 
This triggers the DNA mismatch repair (MMR) system that does not repair O6-methylated 182 
guanine residues but tries to correct the nucleotide on the newly synthesised strand (Jiricny, 183 
2006). As the MMR system cannot find the correct partner, it will reinsert thymidines during 184 
the repair process. A futile cycle of repetitive non-productive repairs is the result leading to 185 
the accumulation of persistent nicks in the DNA during the subsequent cell cycle. These 186 
nicks ultimately inhibit initiation of replication inducing blockage of the cell cycle at the G2-187 
M boundary. Subsequently, the DNA will fragment and the cell dies. The observed effect of 188 
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temozolomide on the DNA content of trypanosomes exposed to the drug (increased G2-M 189 
peak and increased sub-G1 peak), is consistent with the cytotoxic mechanism mediated 190 
through base modification recognised by the MMR machinery as describe above. 191 
Combination therapy has been shown to be a valuable option for the treatment of 192 
parasitic infections. For instance, the first-line recommended treatments of malaria and 193 
sleeping sickness are, according the World Health Organization, dual-drug therapies (WHO, 194 
2016, 2017). Therefore, the interaction of temozolomide with the two drugs used in second 195 
stage treatment of sleeping sickness, eflornithine and melarsoprol, was evaluated with the 196 
fixed-ratio isobologram method (Fivelman et al., 2004). The experimental design allowed the 197 
determination of FIC values for each combination (Tables 1 and 2). Both 198 
temozolomide/eflornithine and temozolomide/melarsoprol combinations had FIC values 199 
ranging between 1.1 and 1.4. The xFIC of both combinations was very similar with 200 
calculated values of 1.27±0.06 (temozolomide/eflornithine) and 1.29±0.13 201 
(temozolomide/melarsoprol) which were not significantly different (p = 0.737, student’s t-202 
test). As these xFIC values are within the range of 0.5 to 4, the interaction between 203 
temozolomide and the two anti-trypanosomal drugs is indifferent (additive) (Odds, 2003). 204 
The indifferent interaction was also confirmed by plotting the individual FIC values in 205 
isobolograms (Fig. 4), where all points were close to the additivity line. 206 
Temozolomide is an oral alkylating prodrug that is 100% bioavailable and able to cross 207 
the blood-brain barrier (Agarwala and Kirkwood, 2000). The prodrug is stable at the acidic 208 
pH of the stomach but spontaneously converts to the active metabolite 5-(3-dimethyl-1-209 
triazenyl) imidazole-4-carboxamide when in contact with the slightly basic pH of the blood 210 
and tissues (Newlands et al., 1997). The concentrations of the temozolomide in the brain and 211 
cerebrospinal fluid (CSF) are about 30% of plasma levels (Agarwala and Kirkwood, 2000). 212 
These pharmacological properties make the drug an interesting agent for treating the 213 
neurological stage of sleeping sickness. The mean peak CSF concentration of temozolomide 214 
in Rhesus monkeys receiving the drug as a 1 h intravenous infusion was 26±4 μM at 2.5 h 215 
(Patel et al., 2003). Although this concentration is close to the GI50 value determined for 216 
bloodstream forms of T. brucei in vitro, it is arguable whether it would be high enough to 217 
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significantly affect the growth of the CSF forms of the parasites. However, in contrast to 218 
bloodstream forms, CSF forms are more fragile and lyse quickly (Pentreath et al., 1992) 219 
which could indicate that they may be also more susceptible to drugs. It remains to be shown 220 
in an animal model for the second stage of the disease whether temozolomide can indeed 221 
eliminate trypanosomes from the brain. 222 
Rather employing temozolomide as monotherapy, it would be probably more promising 223 
to use the drug in combination with eflornithine or melarsoprol. Although the combination of 224 
temozolomide with the anti-trypanosomal drugs did not result in the desirable synergistic 225 
interaction, an additive (indifferent) effect is also of value as it would permit decreased 226 
dosage while maintaining efficacy (Chou, 2006). In this context it is interesting to note that 227 
the recommended nifurtimox/eflornithine combination therapy as first-line treatment of the 228 
second stage of sleeping sickness failed to show synergistic anti-trypanosomal activity in 229 
vitro (Vincent et al., 2012). Further investigations are requires to establish the in vivo efficacy 230 
of temozolomide in combination with eflornithine or melarsoprol. 231 
As for many anti-cancer drugs, temozolomide causes side effects but is usually well 232 
tolerated. The most common adverse events are nausea, vomiting, headache, fatigue and 233 
constipation with severity levels generally being mild to moderate (Agarwala and Kirkwood, 234 
2000). Thus, the side effects of temozolomide are similar or less severe than those of the anti-235 
HAT drugs currently used for treatment of second stage sleeping sickness (Abdi et al., 1995). 236 
The relative low anti-trypanosomal activity of temozolomide should not discourage from 237 
carrying out further research into this compound. For example, nifurtimox is also not very 238 
trypanocidal (GI50 for bloodstream form trypanosomes was determined to be between 4 to 5.6 239 
μM (Enanga et al., 2003; Vincent et al., 2012)), and yet the nitroheterocyclic drug has 240 
become in combination with eflornithine the first-line treatment of late stage sleeping 241 
sickness. In addition, temozolomide has been shown to be active in patients with high-grade 242 
gliomas (Agarwala and Kirkwood, 2000), despite the drug has a similar low activity against 243 
glioblastoma cells in vitro as against trypanosomes. In this context it should also be noted that 244 
in vitro studies not necessarily reflect the situation in vivo. For instance, the host’s immune 245 
response may contribute to the effect of drugs and pharmacokinetic factors may lead to a 246 
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different exposure of pathogens to drugs. Importantly, alkylating agents have been previously 247 
shown to eliminate trypanosomes from the bloodstream of mice within 48-72 h (Penketh et 248 
al., 1990). 249 
In summary, we have shown that the glioblastoma chemotherapeutic agent 250 
temozolomide is toxic to bloodstream forms of T. brucei and potently enhances the activity of 251 
the existing drugs eflornithine and melarsoprol. As temozolomide is a clinically approved 252 
oral chemotherapy with well-established pharmacokinetic data and if the agent is 253 
demonstrated to be effective against trypanosomes in vivo, a more rapid application of the 254 
drug for treatment of second stage sleeping sickness with less extensive clinical trials might 255 
be possible, particularly in combination with eflornithine or melarsoprol. 256 
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Table 1 357 
GI50 and FIC values of temozolomide-eflornithine combination against bloodstream forms of T. brucei. 358 
Combination ratio (%)  GI50±SD (95% CI
c)  FIC   
TMZa DFMOb  TMZ (μM) DFMO (μM)  TMZ DFMO  FICd 
100 0  27.1±0.8 (25.5-28.7)       
80 20  24.8±0.4 (24.0-25.6) 5.2±0.1 (5.0-5.4)  0.92 0.27  1.19 
60 40  19.9±0.8 (18.3-21.5) 11.1±0.5 (10.1-12.0)  0.73 0.57  1.30 
40 60  13.2±0.8 (11.7-14.7) 16.5±0.9 (14.7-18.3)  0.49 0.84  1.33 
20 80  6.0±0.8 (4.4-7.5) 19.9±2.6 (14.9-24.9)  0.22 1.02  1.24 
0 100   19.6±2.6 (14.5-24.7)      
a TMZ, temozolomide. 359 
b DFMO, eflornithine (DL-α-difluoromethylornithine). 360 
c CI, confidence interval. 361 
d FIC, sum of FIC values. 362 
  363 
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Table 2 364 
GI50 and FIC values of temozolomide-melarsoprol combination against bloodstream forms of T. brucei. 365 
Combination ratio (%)  GI50±SD (95% CI
c)  FIC   
TMZa MEb  TMZ (μM) ME (nM)  TMZ ME  FICd 
100 0  27.7±0.5 (26.7-28.4)       
80 20  25.8±0.7 (24.5-27.1) 0.9±0.0 (0.8-0.9)  0.93 0.18  1.11 
60 40  25.6±0.8 (24.0-27.2) 2.3±0.1 (2.1-2.4)  0.92 0.45  1.37 
40 60  18.4±0.4 (17.7-19.1) 3.7±0.1 (3.5-3.8)  0.66 0.73  1.39 
20 80  9.2±0.3 (8.5-9.9) 4.9±0.2 (4.5-5.3)  0.33 0.96  1.29 
0 100   5.1±0.0 (5.1-5.2)      
a TMZ, temozolomide. 366 
b ME, melarsoprol. 367 
c CI, confidence interval. 368 
d FIC, sum of FIC values. 369 
 370 
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Figure legends 371 
 372 
Fig. 1. Chemical structure of temozolomide (4-methyl-5-oxo-2,3,4,6,8-373 
pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide). The PubChem Compound Identifier 374 
(CID) of the compound is 5394. 375 
 376 
Fig. 2. Effect of temozolomide on the growth of bloodstream forms of T. brucei and human 377 
myeloid leukaemia HL-60 cells. Trypanosomes (circles) and HL-60 cells (squares) were 378 
incubated with varying concentrations of temozolomide. After 72 h of culture, cell viability 379 
and proliferation was determined with the colorimetric dye resazurin. Mean values ± SD of 380 
three experiments are shown. 381 
 382 
Fig. 3. Cell cycle distribution of bloodstream forms of T. brucei exposed to temozolomide. 383 
Trypanosomes were treated with 100 μM temozolomide (red line) or with 0.5% DMSO 384 
(black line, control). After 21 h incubation, the cells were stained with propidium iodide and 385 
the DNA content analysed by flow cytometry. The gates M1, M2 and M3 represent cell 386 
populations with less than the normal DNA contend (<2C), with normal DNA content (2C) 387 
and with double DNA content (4C). The respective gated populations comprised M1 = 4.9%, 388 
M2 = 71.0% and M3 = 23.5% of cells for the control parasites and M1= 31.4%, M2 = 25.6% 389 
and M3 = 41.1% of cells for the temozolomide-treated trypanosomes. It should be noted that 390 
the population distribution of control cells is consistent to previously observations for 391 
bloodstream forms of T. brucei (Kabani et al., 2010). 392 
 393 
Fig. 4. Isobolograms showing the in vitro interactions between temozolomide and 394 
eflornithine (A) and between temozolomide and melarsoprol (B) against bloodstream forms 395 
of T. brucei. Assays were performed by a fixed-ratio method based on GI50 values, with the 396 
combinations being tested at constant ratios of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5. Results shown 397 
are from three independent experiments (see Tables 1 and 2). The dashed line is the 398 
theoretical line that produced a sum of the FICs of 1 at all ratios tested and represents an 399 
17 
 
additive effect of the two compounds. The xFIC values shown are the mean sums of the 400 
FICs for the interactions tested. 401 
  402 
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Fig. 1 403 
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Fig. 2 408 
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Fig. 3 412 
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Fig. 4 417 
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